Baxter International Inc. ($BAX) Stock Forecast: Down 5.1% Today

What is Baxter International Inc.?

Baxter International (BAX) is a leading global healthcare company that focuses on innovative medical devices, pharmaceuticals, and biotechnology. The company recently divested its Kidney Care business to concentrate on medtech and hospital products, aiming to improve margins and cash generation.

Why is Baxter International Inc. going down?

BAX stock is down 5.1% on Jun 17, 2026 19:46

• Baxter International's stock dropped 1.68% on Tuesday, going against the overall market trend.
• Concerns among investors may have arisen due to the company's recent divestment of its Kidney Care business and its strategic focus on medtech and hospital products to boost profitability.
• Despite positive performances in Advanced Surgery and Healthcare Technology, challenges such as weak core business performance and margin compression from external pressures could have contributed to the stock's decline.
• Uncertainties surrounding Baxter's management of regulatory issues with its Novum infusion pump and its efforts to enhance the balance sheet amidst the competitive healthcare landscape might be influencing the market's reactions.

BAX Price Chart

BAX Technical Analysis

BAX News

Global 3D Printing Medical Devices Market Leaders Advancing Next-Generation Healthcare Technologies

The global 3D Printing Medical Devices Market is experiencing rapid growth, driven by increasing adoption of customized medical devices, advanced manufacturing technologies, and precision medicine. The market is projected to reach USD 18.61 Billion by 2035, growing at a CAGR of 17.49%. Key players like Stratasys Ltd., 3D Systems Corporation, and Materialise NV are innovating in patient-specific devices, integrated additive manufacturing, and surgical planning, contributing to enhanced patient outcomes and reduced costs in healthcare.

https://www.snsinsider.com/blogs/3d-printing-medical-devices-industry

Baxter’s Post-Divestiture Profit Focus Might Change The Case For Investing In Baxter International (BAX)

Baxter International recently divested its Kidney Care business, aiming to focus on medtech and hospital products to improve margins and cash generation. While Q1 2026 results showed modest sales growth and improved operating cash flow, the company still reported a net loss. Investors are now closely watching how quickly Baxter can convert its large installed base and recurring consumables into sustainable profitability and a stronger balance sheet, despite potential margin pressures.

https://simplywall.st/stocks/us/healthcare/nyse-bax/baxter-international/news/baxters-post-divestiture-profit-focus-might-change-the-case

Reasons to Retain Baxter International Stock in Your Portfolio for Now

Baxter International (BAX) is implementing a turnaround strategy to restore growth and improve financial performance, with some positive factors like strong performance in Advanced Surgery and Healthcare Technology, and growing integration of AI. However, the company faces significant challenges including weak core business performance, regulatory issues with its Novum infusion pump, and severe margin compression due to external pressures. Despite these headwinds, the article suggests retaining the stock due to its long-term outlook supported by innovation and balance-sheet improvements.

https://finance.yahoo.com/markets/stocks/articles/reasons-retain-baxter-international-stock-181400916.html

Baxter International Inc. stock underperforms Tuesday when compared to competitors

Baxter International Inc. (BAX) shares dropped 1.68% on Tuesday, closing at $20.46. This performance was in contrast to a mixed trading day where the Dow Jones Industrial Average rose and the S&P 500 Index fell. This marks the second straight day of losses for the stock.

https://www.marketwatch.com/data-news/baxter-international-inc-stock-underperforms-tuesday-when-compared-to-competitors-016e5ff0-1a3ebe67421d?mod=mw_quote_news

BTIG initiates ICU Medical stock coverage with buy rating

BTIG has initiated coverage on ICU Medical Inc. (NASDAQ:ICUI) with a Buy rating and a price target of $170.00, citing the company's pure-play infusion therapy business and potential for market share gains from competitors. The firm anticipates ICU Medical's free cash flow to improve as integration costs wind down and expects gross margins to reach 43% by late 2027. Recent developments include strong Q1 2026 earnings, a Needham upgrade, and shareholder approval of charter amendments simplifying voting requirements.

https://m.uk.investing.com/news/stock-market-news/btig-initiates-icu-medical-stock-coverage-with-buy-rating-93CH-4727627?ampMode=1

Trending Today

Adobe Inc. ($ADBE) Stock Forecast: Down 5.4% Today

Upwork Inc. ($UPWK) Stock Forecast: Down 5.2% Today

CarMax Inc ($KMX) Stock Forecast: Down 9.9% Today

Gap Inc. ($GAP) Stock Forecast: Down 3.6% Today

Alexandria Real Estate Equities Inc. ($ARE) Stock Forecast: Down 5.4% Today

Baxter International Inc. ($BAX) Stock Forecast: Down 5.1% Today

Franklin Resources Inc. ($BEN) Stock Forecast: Up 0.4% Today

Moderna Inc. ($MRNA) Stock Forecast: Up 10.8% Today

Robinhood Inc. ($HOOD) Stock Forecast: Up 9.4% Today

Meta Platforms, Inc. ($META) Stock Forecast: Down 5.2% Today

Baxter International Inc. Price History

01.03.2026 - BAX Stock was up 5.1%

• The bullish movement in Baxter International Inc. (BAX) stock can be attributed to the launch of its IV Verify Line Labeling System, showcasing the company's commitment to improving patient safety and nurse productivity in clinical settings.
• The positive market response indicates investor confidence in Baxter's strategic developments and potential for revenue growth in the global intravenous solutions market.
• Despite some recent declines in stock performance, this innovative product launch has reignited investor interest and positioned Baxter International for further market expansion and success in the healthcare industry.

30.03.2026 - BAX Stock was up 5.4%

• Despite reporting a Q1 loss, Baxter International Inc. (BAX) experienced a strong bullish movement in the stock market.
• The bullish trend could be attributed to the company's ability to surpass Wall Street expectations in terms of adjusted earnings per share and revenue.
• Investors may be optimistic about Baxter's strategic initiatives post the Kidney Care divestiture and the company's reiterated full-year guidance, which could indicate stability and growth potential.
• The positive market response to Baxter's financial results suggests that investors are focusing more on the company's long-term outlook and operational performance rather than short-term losses.

30.03.2026 - BAX Stock was up 3.2%

• Despite posting a Q1 loss, Baxter International Inc. experienced a strong bullish movement in the stock market.
• The bullish trend could be attributed to the company's robust sales performance, with revenue exceeding expectations and demonstrating a 5% year-over-year increase.
• Investors may have been encouraged by Baxter's resilience in the face of challenges like higher costs and tariffs, as well as the company's reaffirmation of its full-year guidance and strategic initiatives.
• The market reaction, with the stock soaring 7.6%, indicates investor confidence in Baxter's ability to navigate the medtech market landscape and drive long-term growth.

10.05.2026 - BAX Stock was up 5.1%

• Baxter's bullish movement today can be attributed to the exclusive supply and distribution agreement with MediThinQ for its 3D surgical visualization solution 'SHIYA'. This partnership is seen as a strategic move to enhance Baxter's surgical technology offerings and expand its market presence.
• The increasing demand for home dialysis services could also be positively impacting Baxter's stock, given its involvement in renal products and therapies.
• Ceribell's AI-powered algorithm study showcasing improved patient outcomes in critical care settings might be boosting investor confidence in healthcare companies like Baxter, known for their innovative medical solutions.
• The appointment of Ludwig Hantson, a seasoned biopharmaceutical executive, to Ionis Pharmaceuticals' board could be signaling positive industry sentiment, potentially benefiting other healthcare-related stocks like Baxter.

27.02.2026 - BAX Stock was down 5.2%

• Baxter International Inc. (BAX) experienced a substantial 2.63% drop to $16.67, halting a previous positive trend in concurrence with the broader bearish market conditions.
• Following a downgrade in the outlook by S&P, citing concerns about leverage and free cash flow, Bank of America maintained a Hold rating on BAX.
• Investor interest heightened due to a recent CFO change at Baxter International, with the stock trading below its estimated fair value, hinting at potential undervaluation.
• Despite The Vanguard Group reporting 0% ownership post an internal rearrangement, which had no substantial impact on the stock's performance, as it was merely an administrative adjustment.

14.03.2026 - BAX Stock was up 5.6%

• Baxter International Inc. showcased its latest innovations, including the AAT XR spine surgical table and Dynamo Series smart stretcher, at the AORN Global Surgical Conference & Expo. These new products aim to improve efficiency, support safer patient care, and address common challenges faced by healthcare teams in surgical settings.
• The company's stock outperformed competitors on a strong trading day, rising by 2.80%. This positive market reaction could be attributed to investor optimism surrounding Baxter's commitment to evolving its portfolio through collaboration with healthcare professionals and its focus on enhancing efficiency and patient care.
• The emphasis on Baxter's new surgical and patient support products, designed to enhance efficiency, streamline workflows, and improve patient care in operating rooms, likely contributed to the bullish movement in the stock price.
• Overall, the market responded positively to Baxter's innovative product showcase at the conference, reflecting investor confidence in the company's ability to drive growth and address the evolving needs of the healthcare industry.

29.03.2026 - BAX Stock was down 5.6%

• Baxter International Inc. (BAX) stock declined by 2.97% on Tuesday, performing below market indices.
• Analysts predict stagnant year-on-year revenue for Q1 earnings, indicating a slowdown compared to previous periods.
• Challenges in product categories aimed at hospitals and unfavorable comparisons are expected to have a negative impact on revenue.
• BlackRock Inc.'s 6.4% ownership filing in Baxter International Inc. may have affected market sentiment, contributing to the bearish trend.

29.03.2026 - BAX Stock was down 5.3%

• Baxter International Inc. (BAX) stock experienced a strong bearish movement, falling 2.97% to $17.94, underperforming the market indices.
• The stock's underperformance could be attributed to the broader market decline, as both the S&P 500 Index and Dow Jones Industrial Average also saw decreases.
• Despite the company's positive Q1 earnings report and potential for recovery, the market pressures and the stock closing significantly below its 52-week high might have contributed to the bearish movement.
• The filing by BlackRock Inc. showing a 6.4% ownership of Baxter International Inc. shares could also be a factor influencing market sentiment, although not directly causing the bearish movement.

31.02.2026 - BAX Stock was up 5.0%

• Baxter International experienced a bullish movement following the successful launch of its IV Verify Line Labeling System, designed to enhance IV medication accuracy and minimize errors in clinical environments.
• Market response has been positive towards Baxter's efforts to reinforce its infusion therapy ecosystem, as demonstrated by its partnership with Vigilant Software to address compliance issues and streamline nurse operations.
• Despite recent stock declines, investor outlook appears bullish on Baxter's ability to leverage the growing intravenous solutions market with this new technology, contributing to today's positive performance.
• The introduction of this cutting-edge system underscores Baxter's dedication to innovation and patient safety, potentially increasing investor trust and driving the stock's upward momentum amid a day of mixed trading in the broader market.

17.03.2026 - BAX Stock was up 8.2%

• Baxter International Inc. stock witnessed a notable surge today, possibly due to its defensive growth profile and focus on essential hospital products.
• The company's strong position in the healthcare sector, emphasizing its hospital supply advantage, could have attracted investors seeking stability in uncertain economic times.
• With the increasing demand for crucial medical supplies, Baxter International Inc.'s stock performance may be benefiting from the rising need for its products, particularly in the expanding Blood And Blood Components Market.
• The generally positive market outlook towards healthcare stocks, alongside Baxter International Inc.'s robust business model and market positioning, likely played a role in its bullish movement today.

04.05.2026 - BAX Stock was up 5.3%

• Baxter's stock witnessed a bullish movement recently, driven by internal factors like executive stock transactions and equity grants. These actions signal confidence and stability within the company's leadership.
• The launch of the IV Verify Line Labeling System highlights Baxter's ongoing focus on innovation and patient safety, which could attract investor attention and contribute to stock price growth.
• The growth of the refurbished medical equipment industry, with industry leaders like GE HealthCare and Siemens Healthineers, might have positively influenced Baxter's stock performance as part of the broader healthcare sector trend. Investors may see Baxter as well-prepared to capitalize on industry growth and technological advancements.

17.05.2026 - BAX Stock was down 5.1%

• Baxter International's stock dropped 1.68% on Tuesday, going against the overall market trend.
• Concerns among investors may have arisen due to the company's recent divestment of its Kidney Care business and its strategic focus on medtech and hospital products to boost profitability.
• Despite positive performances in Advanced Surgery and Healthcare Technology, challenges such as weak core business performance and margin compression from external pressures could have contributed to the stock's decline.
• Uncertainties surrounding Baxter's management of regulatory issues with its Novum infusion pump and its efforts to enhance the balance sheet amidst the competitive healthcare landscape might be influencing the market's reactions.